Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a primary liver cancer with rising incidence globally, spurred by chronic liver diseases like hepatitis B and C, and non-alcoholic fatty liver disease. Current cancer research is focusing on the molecular mechanisms and genetic mutations driving HCC progression. Breakthroughs in understanding the tumor microenvironment, immune evasion strategies, and angiogenesis have opened new avenues for targeted therapies. Immunotherapies, particularly checkpoint inhibitors, are showing promise in clinical trials, offering hope for improved survival rates. Additionally, advancements in liquid biopsy techniques for early detection and monitoring are enhancing personalized treatment approaches. Continuous research is vital for developing innovative strategies to combat HCC and improve patient outcomes.